887 related articles for article (PubMed ID: 28745999)
1. Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
Stone JH; Han J; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Unizony SH; Bao M;
Lancet Rheumatol; 2021 May; 3(5):e328-e336. PubMed ID: 38279390
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for giant cell arteritis.
Antonio AA; Santos RN; Abariga SA
Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for giant cell arteritis.
Antonio AA; Santos RN; Abariga SA
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204
[TBL] [Abstract][Full Text] [Related]
5. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
Venhoff N; Schmidt WA; Bergner R; Rech J; Unger L; Tony HP; Finzel S; Andreica I; Kofler DM; Weiner SM; Lamprecht P; Schulze-Koops H; App C; Pournara E; Mendelson MH; Sieder C; Maricos M; Thiel J
Lancet Rheumatol; 2023 Jun; 5(6):e341-e350. PubMed ID: 38251601
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
[TBL] [Abstract][Full Text] [Related]
10. Treatment failure in giant cell arteritis.
Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Cid MC; Unizony SH; Blockmans D; Brouwer E; Dagna L; Dasgupta B; Hellmich B; Molloy E; Salvarani C; Trapnell BC; Warrington KJ; Wicks I; Samant M; Zhou T; Pupim L; Paolini JF;
Ann Rheum Dis; 2022 May; 81(5):653-661. PubMed ID: 35264321
[TBL] [Abstract][Full Text] [Related]
13. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
[TBL] [Abstract][Full Text] [Related]
14. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.
Unizony S; Matza MA; Jarvie A; O'Dea D; Fernandes AD; Stone JH
Lancet Rheumatol; 2023 Dec; 5(12):e736-e742. PubMed ID: 38251564
[TBL] [Abstract][Full Text] [Related]
15. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera RF; Unizony S; Warrington KJ; Sloane J; Giannelou A; Nivens MC; Akinlade B; Wong W; Bhore R; Lin Y; Buttgereit F; Devauchelle-Pensec V; Rubbert-Roth A; Yancopoulos GD; Marrache F; Patel N; Dasgupta B;
N Engl J Med; 2023 Oct; 389(14):1263-1272. PubMed ID: 37792612
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
Bonelli M; Radner H; Kerschbaumer A; Mrak D; Durechova M; Stieger J; Husic R; Mandl P; Smolen JS; Dejaco C; Aletaha D
Ann Rheum Dis; 2022 Jun; 81(6):838-844. PubMed ID: 35210264
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
Seror R; Baron G; Hachulla E; Debandt M; Larroche C; Puéchal X; Maurier F; de Wazieres B; Quéméneur T; Ravaud P; Mariette X
Ann Rheum Dis; 2014 Dec; 73(12):2074-81. PubMed ID: 23897775
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y; Isobe M; Takei S; Tanaka Y; Ishii T; Yokota S; Nomura A; Yoshida S; Nishimoto N
Ann Rheum Dis; 2018 Mar; 77(3):348-354. PubMed ID: 29191819
[TBL] [Abstract][Full Text] [Related]
20. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
